M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 28.41 CNY 0.07% Market Closed
Market Cap: 12.2B CNY
Section:
 

Relative Value

The Relative Value of one Mayinglong Pharmaceutical Group Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 28.41 CNY, Mayinglong Pharmaceutical Group Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Mayinglong Pharmaceutical Group Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

3.2
P/S
P/S
Price to Sales
3.2
vs History
36
vs Industry
37
Median 3Y
3.2
Median 5Y
3.1
Industry
2.6
Forward
2.8
More Details
21.4
P/E
P/E
Price to Earnings
21.4
vs History
49
vs Industry
21
Median 3Y
21.6
Median 5Y
21.4
Industry
21.7
Forward
19.3
More Details
19.4
P/OCF
P/OCF
Price to OCF
19.4
vs History
52
vs Industry
32
Median 3Y
19.4
Median 5Y
20.4
Industry
16.6
More Details
29.3
P/FCFE
P/FCFE
Price to FCFE
29.3
vs History
44
vs Industry
12
Median 3Y
30.8
Median 5Y
26.2
Industry
22.5
More Details
2.8
P/B
P/B
Price to Book Value
2.8
vs History
58
vs Industry
28
Median 3Y
2.9
Median 5Y
2.9
Industry
2.3
More Details
3.3
EV/S
EV/S
Enterprise Value to Sales
3.3
vs History
3
vs Industry
45
Median 3Y
2.5
Median 5Y
2.4
Industry
2.9
Forward
2.8
More Details
7
EV/GP
EV/GP
Enterprise Value to Gross Profit
7
vs History
7
vs Industry
39
Median 3Y
5.6
Median 5Y
5.6
Industry
5.5
More Details
19.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
19.5
vs History
19
vs Industry
24
Median 3Y
16.8
Median 5Y
16.7
Industry
13.1
Forward
14.8
More Details
19.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
19.5
vs History
19
vs Industry
28
Median 3Y
16.8
Median 5Y
16.7
Industry
16.6
Forward
16.8
More Details
19.6
EV/OCF
EV/OCF
Enterprise Value to OCF
19.6
vs History
38
vs Industry
39
Median 3Y
16.2
Median 5Y
16.4
Industry
15.8
More Details
22.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
22.6
vs History
44
vs Industry
27
Median 3Y
22.5
Median 5Y
22
Industry
19.1
More Details
2.5
EV/IC
EV/IC
Enterprise Value to IC
2.5
vs History
95
vs Industry
18
Median 3Y
4.4
Median 5Y
4.3
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Mayinglong Pharmaceutical Group Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
12.2B CNY 3.2 21.4 19.5 19.5
US
Eli Lilly and Co
NYSE:LLY
946.5B USD 15.9 51.2 34.6 37
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
484B USD 5.3 19.3 15.8 20.5
CH
Roche Holding AG
SIX:ROG
252.4B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
209.5B GBP 4.8 29.7 108.2 158.3
CH
Novartis AG
SIX:NOVN
204.5B CHF 4.5 17.7 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
244.6B USD 3.8 12.8 9.2 10.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.8 9 10.5
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
147.3B USD 2.4 14.9 7.6 10.4
P/E Multiple
Earnings Growth PEG
CN
M
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Average P/E: 23
21.4
17%
1.3
US
Eli Lilly and Co
NYSE:LLY
51.2
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.7
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
12.8
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
4%
3.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
M
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Average EV/EBITDA: 399.5
19.5
22%
0.9
US
Eli Lilly and Co
NYSE:LLY
34.6
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.8
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9
2%
4.5
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
M
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Average EV/EBIT: 1 709.3
19.5
17%
1.1
US
Eli Lilly and Co
NYSE:LLY
37
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.3
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.9
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
1%
10.5
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 301,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.